Business Context and Reporting Period
Company: Sunshine Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 9, 2023
Reporting Period: Single event date (February 9, 2023)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory compliance event rather than financial performance.
Material Changes
On February 9, 2023, the Company received notice from the Nasdaq Listing Qualifications Staff confirming that it has regained compliance with Nasdaq's minimum $1 bid price per share requirement.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies beyond the resolution of the specific listing deficiency regarding the minimum bid price.
Investor Verification Checklist
- Verify the current trading price of Common Stock (SBFM) on The Nasdaq Stock Market LLC to confirm sustained compliance with the $1.00 minimum bid price rule.
- Review prior 8-K filings to understand the duration and nature of the previous non-compliance period.
- Confirm the status of Common Stock Purchase Warrants (SBFMW) listed on the same exchange.